Jazz secures FDA approval for Ziihera in advanced HER2+ GEA

The FDA has approved two Jazz Pharmaceuticals regimens containing Ziihera for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA. The decision follows results from the Phase III HERIZON-GEA-01 trial, which showed significant improvements with Ziihera-based treatments. Ziihera, a bispecific HER2-directed antibody, is also indicated in the US for previously treated HER2+ biliary tract cancer. Credit: Arif biswas / Shutterstock.com. The US Food and Drug Administration (FDA) has approved two Jazz Pharmaceuticals regimens containing Ziihera (zanidatamab-hrii) for the first-line treatment of adults with unresectable, locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal…

Salong Debbarma · 2026-08-26

The FDA has approved two Jazz Pharmaceuticals regimens containing Ziihera for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA.

Source: Pharmaceutical Technology